Prevention of 5-fluorouracil–induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: The multiparametric approach is not convincing

Marie-Christine Etienne-Grimaldi (1) , Chantal Barin Le Guellec (2) , Jean-Christophe Boyer (3) , Etienne Chatelut (4) , Alexandre Evrard (3, 5) , Marie-Anne Loriot (6) , Angelo Paci (7) , Bernard Royer (8) , Fabienne Thomas (4) , Joseph Ciccolini (9, 10)

1 UNICANCER/CAL - Centre de Lutte contre le Cancer Antoine Lacassagne [Nice]
2 CHRU Tours - Centre Hospitalier Régional Universitaire de Tours
3 Laboratoire de Biochimie [CHRU Nîmes]
4 Institut Claudius Regaud
5 IRCM - U1194 Inserm - UM - Institut de Recherche en Cancérologie de Montpellier
6 HEGP - Hôpital Européen Georges Pompidou [APHP]
7 Département de pharmacie clinique [Gustave Roussy]
8 CHRU Besançon - Centre Hospitalier Régional Universitaire de Besançon
9 SMARTc - Simulation and Modeling of Adaptive Response for Therapeutics in Cancer
10 Pharmacocinétique Toxicocinétique - [Hôpital de la Timone - APHM]

Domaines: Cancer

Marie-Christine Etienne-Grimaldi, Chantal Barin Le Guellec, Jean-Christophe Boyer, Etienne Chatelut, Alexandre Evrard, et al.. Prevention of 5-fluorouracil–induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: The multiparametric approach is not convincing. Seminars in Oncology Nursing, 2017, 44 (2), pp.159 - 160. ⟨10.1053/j.seminoncol.2017.06.001⟩. ⟨hal-01892184⟩